Increasing Skeletal Muscle Mass and Strength During Incretin-Based Weight Loss

Incretin-based therapies produce robust weight loss in obesity and type 2 diabetes mellitus (T2DM), but a substantial proportion of weight lost is lean body mass (LBM), raising concern about sarcopenia and functional decline. Hypogonadal men with obesity and T2DM are particularly predisposed to muscle loss. Whether concurrent anabolic therapy can preserve skeletal muscle mass (SMM) during incretin-mediated weight loss remains unknown. This retrospective case series reports on the results of 93 hypogonadal men (BMI ≥30 kg/m², testosterone